INTERVENTION 1:	Intervention	0
ER+ and/or PgR+ (Arm I)	Intervention	1
Panobinostat - LBH589: hard gelatine capsule - 5mg and 20mg	Intervention	2
panobinostat	CHEBI:85990	0-12
capsule	GO:0042603	37-44
INTERVENTION 2:	Intervention	3
ER- and PgR- (Arm II)	Intervention	4
Panobinostat - LBH589: hard gelatine capsule - 5mg and 20mg	Intervention	5
panobinostat	CHEBI:85990	0-12
capsule	GO:0042603	37-44
Inclusion Criteria:	Eligibility	0
Written informed consent obtained prior to any study-related procedures	Eligibility	1
Women  18 years old	Eligibility	2
Patients with an ECOG performance status of  2 assessed within 2 weeks (14 days) prior to registration	Eligibility	3
Histologically or cytologically confirmed breast cancer with locally recurrent or radiological evidence of metastatic disease. Locally recurrent disease must not be amenable to resection with curative intent.	Eligibility	4
breast cancer	DOID:1612	42-55
recurrent	HP:0031796	69-78
recurrent	HP:0031796	135-144
disease	DOID:4,OGMS:0000031	118-125
disease	DOID:4,OGMS:0000031	145-152
Measurable disease per RECIST (Response Evaluation Criteria in Solid Tumor) guidelines	Eligibility	5
disease	DOID:4,OGMS:0000031	11-18
HER2-negative patients by local laboratory testing (IHC 0 or 1+ staining, IHC 2+ staining but in situ hybridization negative, or in situ hybridization negative).	Eligibility	6
ER and PgR testing from a local laboratory is required prior to patient registration	Eligibility	7
patient	HADO:0000008,OAE:0001817	64-71
For Arm I: at least two lines of prior endocrine therapy (in adjuvant and/or metastatic settings) are required. Up to two prior cytotoxic chemotherapies are allowed in the metastatic setting (prior adjuvant and neoadjuvant chemotherapy is allowed).	Eligibility	8
adjuvant	CHEBI:60809	61-69
adjuvant	CHEBI:60809	198-206
adjuvant	CHEBI:60809	214-222
For Arm II: up to 2 prior cytotoxic chemotherapy regimens for treatment of metastatic or locally recurrent breast cancer are allowed.	Eligibility	9
recurrent	HP:0031796	97-106
breast cancer	DOID:1612	107-120
Complete radiological tumor measurement within 4 weeks (28 days) prior to registration:	Eligibility	10
tumor measurement	CMO:0000341	22-39
Chest: CT scan with intravenous contrast if the contrast is not medically contraindicated or MRI	Eligibility	11
chest	UBERON:0001443	0-5
ct	BAO:0002125	7-9
Abdomen: CT scan with intravenous or oral contrast if the contrast is not medically contraindicated or MRI	Eligibility	12
abdomen	UBERON:0000916	0-7
ct	BAO:0002125	9-11
Brain: CT scan or MRI	Eligibility	13
brain	UBERON:0000955	0-5
ct	BAO:0002125	7-9
Bone: Whole body Bone Scintigraphy	Eligibility	14
Patients must meet the following laboratory criteria within 2 weeks (14 days) prior to registration:	Eligibility	15
Hematology	Eligibility	16
Neutrophil count of > 1200/mm3	Eligibility	17
Platelet count of > 100,000/mm3	Eligibility	18
platelet count	CMO:0000029	0-14
Hemoglobin  90 g/L	Eligibility	19
hemoglobin	CHEBI:35143	0-10
Biochemistry	Eligibility	20
AST/SGOT and ALT/SGPT  2.5 x upper limit of normal (ULN) or  5.0 x ULN if the transaminase elevation is due to disease involvement	Eligibility	21
x	LABO:0000148	27-28
x	LABO:0000148	65-66
disease	DOID:4,OGMS:0000031	111-118
Serum bilirubin  1.5 x ULN	Eligibility	22
x	LABO:0000148	21-22
Serum creatinine  1.5 x ULN or 24-hour creatinine clearance  50 mL/min	Eligibility	23
creatinine	CHEBI:16737	6-16
creatinine	CHEBI:16737	39-49
x	LABO:0000148	22-23
creatinine clearance	CMO:0000765	39-59
Serum potassium, sodium, magnesium, phosphorus, and calcium within normal limits for the institution	Eligibility	24
calcium	CHEBI:22984,BAO:0000874	52-59
Serum albumin  LLN or 30g/L	Eligibility	25
serum albumin	BAO:0002066	0-13
Clinically euthyroid function (TSH and free T4). (Patients are permitted to receive thyroid hormone supplements to treat underlying hypothyroidism).	Eligibility	26
function	BAO:0003117,BFO:0000034	21-29
thyroid hormone	CHEBI:60311	84-99
hypothyroidism	HP:0000821,DOID:1459	132-146
LVEF assessment (2-D echocardiogram or MUGA scan) performed within 6 weeks prior to registration, showing a LVEF value > 50%	Eligibility	27
Electrocardiogram performed within 1 week prior to registration (details about findings on the Electrocardiogram that are not acceptable for participating in the study are reported in the Exclusion criteria section)	Eligibility	28
week	UO:0000034	37-41
Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days prior to registration and agree to appropriate method of pregnancy prevention.	Eligibility	29
Patient should have an archival tumor sample available for confirmation of HER2, Estrogen and Progesterone status by the central lab.	Eligibility	30
patient	HADO:0000008,OAE:0001817	0-7
estrogen	CHEBI:50114,BAO:0000760	81-89
progesterone	CHEBI:17026	94-106
central	HP:0030645	121-128
Exclusion Criteria:	Eligibility	31
Prior HDAC, DAC, HSP90 inhibitors or valproic acid for the treatment of cancer	Eligibility	32
valproic acid	CHEBI:39867	37-50
cancer	DOID:162	72-78
Patients who need valproic acid for any other medical condition during the study or within 5 days prior to first panobinostat treatment	Eligibility	33
valproic acid	CHEBI:39867	18-31
condition	PDRO:0000129	54-63
panobinostat	CHEBI:85990	113-125
Patients who have received prior systemic anti-cancer therapy (cytotoxic chemotherapy, endocrine therapy, targeted therapy, monoclonal antibody or biologic therapy) or investigational agent within the last 4 weeks prior to registration (6 weeks for nitrosoureas and mitomycin; 2 weeks for capecitabine)	Eligibility	34
monoclonal	BAO:0000503	124-134
antibody	GO:0042571,BAO:0000502	135-143
mitomycin	CHEBI:25357	266-275
capecitabine	CHEBI:31348	289-301
Patients who have received prior radiotherapy to  25% of the bone marrow within the last 4 weeks prior to registration; local radiotherapy is allowed however all recently irradiated lesions should not be included in the measurable disease assessment.	Eligibility	35
radiotherapy	OAE:0000235	33-45
radiotherapy	OAE:0000235	126-138
bone marrow	UBERON:0002371	61-72
disease	DOID:4,OGMS:0000031	231-238
Patients who have received prior investigational agents within the last 4 weeks prior to registration	Eligibility	36
Patients with unresolved diarrhea CTCAE grade 1	Eligibility	37
diarrhea	HP:0002014,DOID:13250	25-33
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral panobinostat	Eligibility	38
function	BAO:0003117,BFO:0000034	36-44
disease	DOID:4,OGMS:0000031	51-58
panobinostat	CHEBI:85990	111-123
History of cardiac dysfunction including any one of the following:	Eligibility	39
history	BFO:0000182	0-7
Complete left bundle branch block or obligate use of a cardiac pacemaker or congenital long QT syndrome or history or presence of ventricular tachyarrhythmias or clinically significant resting bradycardia (<50 beats per minute) or QTcF > 450 msec on screening ECG or right bundle branch block and left anterior hemiblock (bifascicular block)	Eligibility	40
left bundle branch block	HP:0011713	9-33
obligate	HP:0040280	37-45
long qt syndrome	DOID:2843	87-103
history	BFO:0000182	107-114
bradycardia	HP:0001662	193-204
minute	UO:0000031	220-226
right bundle branch block	HP:0011712,DOID:13209	267-292
left	HP:0012835	9-13
left	HP:0012835	297-301
Presence of unstable atrial fibrillation (ventricular response rate >100 bpm). Patients with stable atrial fibrillation are allowed in the study provided they do not meet the other cardiac exclusion criteria	Eligibility	41
atrial fibrillation	HP:0005110,DOID:0060224	21-40
atrial fibrillation	HP:0005110,DOID:0060224	100-119
rate	BAO:0080019	63-67
stable	HP:0031915	14-20
stable	HP:0031915	93-99
Previous history angina pectoris or acute MI within 6 months of registration	Eligibility	42
history	BFO:0000182	9-16
angina pectoris	HP:0001681	17-32
acute	HP:0011009,PATO:0000389	36-41
Congestive Heart Failure (New York Heart Association functional classification III-IV)	Eligibility	43
congestive heart failure	HP:0001635,DOID:6000	0-24
heart	UBERON:0000948	11-16
heart	UBERON:0000948	35-40
functional	BAO:0000010	53-63
History of unexplained syncope	Eligibility	44
history	BFO:0000182	0-7
syncope	HP:0001279	23-30
Other clinically significant heart disease (e.g. cardiomyopathy, cardiac artery disease, uncontrolled hypertension, or history of poor compliance with an antihypertensive regimen)	Eligibility	45
heart disease	DOID:114	29-42
cardiomyopathy	HP:0001638,DOID:0050700	49-63
artery disease	DOID:0050828	73-87
hypertension	HP:0000822,DOID:10763	102-114
history	BFO:0000182	119-126
Family history of long QT syndrome, unexplained syncope or unexplained sudden death	Eligibility	46
family history	HP:0032316	0-14
long qt syndrome	DOID:2843	18-34
syncope	HP:0001279	48-55
sudden death	HP:0001699	71-83
Acute or chronic liver or renal disease	Eligibility	47
acute	HP:0011009,PATO:0000389	0-5
chronic	HP:0011010	9-16
liver	UBERON:0002107	17-22
disease	DOID:4,OGMS:0000031	32-39
Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled diabetes mellitus, active untreated or uncontrolled infection, chronic obstructive or chronic restrictive pulmonary disease including dyspnoea at rest from any cause) that could cause unacceptable safety risks or compromise compliance with the protocol	Eligibility	48
severe	HP:0012828	17-23
diabetes mellitus	HP:0000819,DOID:9351	83-100
active	PATO:0002354	102-108
chronic	HP:0011010	146-153
chronic	HP:0011010	169-176
disease	DOID:4,OGMS:0000031	199-206
Concomitant use of drugs with a risk of causing torsades de pointes where such treatments cannot be discontinued or switched to a different medication prior to starting study drug	Eligibility	49
drug	CHEBI:23888	19-23
drug	CHEBI:23888	175-179
Brain metastases, unless patient randomized on study at least 90 days from completion of brain radiotherapy and / or surgery without radiologic or functional evidence of progressive brain metastases, and off corticosteroids above the dose of 7.5 mg prednisone or equivalent; No concurrent radiotherapy for brain metastasis is allowed	Eligibility	50
brain	UBERON:0000955	0-5
brain	UBERON:0000955	89-94
brain	UBERON:0000955	182-187
brain	UBERON:0000955	306-311
patient	HADO:0000008,OAE:0001817	25-32
radiotherapy	OAE:0000235	95-107
radiotherapy	OAE:0000235	289-301
surgery	OAE:0000067	117-124
functional	BAO:0000010	147-157
progressive	HP:0003676	170-181
prednisone	CHEBI:8382	249-259
Clinically significant third space fluid accumulation	Eligibility	51
Concurrent biphosphonates unless if initiated prior to study entry (at least 4 weeks before patient registration)	Eligibility	52
patient	HADO:0000008,OAE:0001817	92-99
Pregnant (i.e., positive beta-human chorionic gonadotropin test) or breast feeding patient	Eligibility	53
chorionic gonadotropin	CHEBI:81570	36-58
breast	UBERON:0000310	68-74
patient	HADO:0000008,OAE:0001817	83-90
Unable to swallow oral medications	Eligibility	54
Not willing to use a double barrier method of non-hormonal birth control. Contraception must be used during the study and for 30 days after last dose of study treatment.	Eligibility	55
Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent	Eligibility	56
history	BFO:0000182	30-37
Outcome Measurement:	Results	0
Objective Response Rate (as Determined by Investigator): the Percentage of Patients Assigned to a Treatment Arm With a Confirmed Best Response of CR or PR.	Results	1
rate	BAO:0080019	19-23
The assessment of overall response (OR) is based on the response of target lesion, of non-target lesion, and on presence of new lesions (RECIST criteria version 1.0 using imaging techniques; as per investigator assessment).	Results	2
target	BAO:0003064	68-74
target	BAO:0003064	90-96
Time frame: 6 years and 2 months	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: ER+ and/or PgR+ (Arm I)	Results	5
Arm/Group Description: Panobinostat - LBH589: hard gelatine capsule - 5mg and 20mg	Results	6
panobinostat	CHEBI:85990	23-35
capsule	GO:0042603	60-67
Overall Number of Participants Analyzed: 33	Results	7
Measure Type: Number	Results	8
Unit of Measure: participants  Complete Response: 0	Results	9
Partial Response: 1	Results	10
Stable Disease / Incompete Response: 13	Results	11
stable	HP:0031915	0-6
disease	DOID:4,OGMS:0000031	7-14
Progressive Disease: 14	Results	12
progressive	HP:0003676	0-11
disease	DOID:4,OGMS:0000031	12-19
Missing: 5	Results	13
Results 2:	Results	14
Arm/Group Title: ER- and PgR- (Arm II)	Results	15
Arm/Group Description: Panobinostat - LBH589: hard gelatine capsule - 5mg and 20mg	Results	16
panobinostat	CHEBI:85990	23-35
capsule	GO:0042603	60-67
Overall Number of Participants Analyzed: 21	Results	17
Measure Type: Number	Results	18
Unit of Measure: participants  Complete Response: 1	Results	19
Partial Response: 0	Results	20
Stable Disease / Incompete Response: 4	Results	21
stable	HP:0031915	0-6
disease	DOID:4,OGMS:0000031	7-14
Progressive Disease: 14	Results	22
progressive	HP:0003676	0-11
disease	DOID:4,OGMS:0000031	12-19
Missing: 2	Results	23
Adverse Events 1:	Adverse Events	0
Total: 12/32 (37.50%)	Adverse Events	1
Anaemia 0/32 (0.00%)	Adverse Events	2
Neutropenia 1/32 (3.13%)	Adverse Events	3
neutropenia	HP:0001875,DOID:1227	0-11
Thrombocytopenia 4/32 (12.50%)	Adverse Events	4
thrombocytopenia	HP:0001873,DOID:1588	0-16
Atrial fibrillation 1/32 (3.13%)	Adverse Events	5
atrial fibrillation	HP:0005110,DOID:0060224	0-19
Cardiac failure congestive 1/32 (3.13%)	Adverse Events	6
Myocardial ischaemia 1/32 (3.13%)	Adverse Events	7
Abdominal discomfort 0/32 (0.00%)	Adverse Events	8
Ascites 1/32 (3.13%)	Adverse Events	9
ascites	HP:0001541	0-7
Constipation 0/32 (0.00%)	Adverse Events	10
constipation	HP:0002019,DOID:2089	0-12
Rectal haemorrhage 1/32 (3.13%)	Adverse Events	11
Vomiting 1/32 (3.13%)	Adverse Events	12
vomiting	HP:0002013	0-8
Fatigue 1/32 (3.13%)	Adverse Events	13
fatigue	HP:0012378	0-7
Adverse Events 2:	Adverse Events	14
Total: 8/20 (40.00%)	Adverse Events	15
Anaemia 1/20 (5.00%)	Adverse Events	16
Neutropenia 0/20 (0.00%)	Adverse Events	17
neutropenia	HP:0001875,DOID:1227	0-11
Thrombocytopenia 1/20 (5.00%)	Adverse Events	18
thrombocytopenia	HP:0001873,DOID:1588	0-16
Atrial fibrillation 0/20 (0.00%)	Adverse Events	19
atrial fibrillation	HP:0005110,DOID:0060224	0-19
Cardiac failure congestive 0/20 (0.00%)	Adverse Events	20
Myocardial ischaemia 0/20 (0.00%)	Adverse Events	21
Abdominal discomfort 1/20 (5.00%)	Adverse Events	22
Ascites 0/20 (0.00%)	Adverse Events	23
ascites	HP:0001541	0-7
Constipation 2/20 (10.00%)	Adverse Events	24
constipation	HP:0002019,DOID:2089	0-12
Rectal haemorrhage 0/20 (0.00%)	Adverse Events	25
Vomiting 0/20 (0.00%)	Adverse Events	26
vomiting	HP:0002013	0-8
Fatigue 0/20 (0.00%)	Adverse Events	27
fatigue	HP:0012378	0-7
